Great Novel Therapeutics Biotech & Medicals (TPEX:7427)

Taiwan · Delayed Price · Currency is TWD

66.10

-1.30 (-1.93%)

Oct 8, 2026, 2:57 PM CST

Market Cap	3.50B +170.5%
Revenue (ttm)	6.21M +248.6%
Net Income	-111.67M
EPS	-2.52
Shares Out	52.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	234,725
Open	67.50
Previous Close	67.40
Day's Range	66.10 - 68.40
52-Week Range	29.25 - 82.80
Beta	0.21
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About TPEX:7427

Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers in Taiwan. The company develops GNTbm-38, an epigenetic immune-activating drug independently developed by GNTbm for cancer immunotherapy; and GNTbm-TKI, a potent inhibitor of TYRO-3, AXL, c-MER, BTK, ROS1, NTRK2, MET, and VEGFR2 for immune regulation, tumor growth inhibition, metastasis and invasion suppresion, and anti-angiogenesis activity. It is also developing Kepida to treat HR+/her-2 advanced breast cancer a... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2013

Employees 23

Stock Exchange Taipei Exchange

Ticker Symbol 7427

Full Company Profile

Financial Performance

In 2025, TPEX:7427's revenue was 1.21 million, a decrease of -28.49% compared to the previous year's 1.69 million. Losses were -97.47 million, -7.10% less than in 2024.

Financial Statements